+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn International Transplant Tumor Registry experience



Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn International Transplant Tumor Registry experience



American Journal of Transplantation 5(4 Pt 1): 775-780



Significant mortality is associated with post-transplant lymphoproliferative disorder (PTLD) in kidney transplant recipients (KTX). Univariate/multivariate risk factor survival analysis of US PTLD KTX reported to Israel Penn International Transplant Tumor Registry from November 1968 to January 2000 was performed. PTLD presented 18 (median) (range 1-310) months in 402 KTX. Death rates were greater for those diagnosed within 6 months (64%) versus beyond 6 months (54%, p = 0.04). No differences in death risk for gender, race, immunosuppression, EBV, B or T cell positivity were identified. Death risk increased for multiple versus single sites (73% vs. 53%, hazards ratio (HR) 1.4). A 1-year increase in age increased HR for death by 2%. Surgery was associated with increased survival (55% vs. 0% without surgery) (p < 0.0001). Patients with allograft involvement, treated with transplant nephrectomy alone (n = 20), had 80% survival versus 53% without allograft removal (n = 15) (p < 0.001). Overall survival was 69% for allograft involvement alone versus 36% for other organ involvement plus allograft (n = 19 alive) (p < 0.0001). Death risk was greater for multiple site PTLD and increasing age, and risks were additive. Univariate analysis identified increased death risk for those not receiving surgery, particularly allograft involvement alone.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 048249305

Download citation: RISBibTeXText

PMID: 15760401

DOI: 10.1111/j.1600-6143.2005.00776.x


Related references

Experience With 274 Cardiac Transplant Recipients With Posttransplant Lymphoproliferative Disorder: A Report From the Israel Penn International Transplant Tumor Registry. Yearbook of Oncology 2006: 197-198, 2006

Experience with 274 cardiac transplant recipients with posttransplant lymphoproliferative disorder: a report from the Israel Penn International Transplant Tumor Registry. Transplantation 78(11): 1676-1682, 2004

Chemotherapy for posttransplant lymphoproliferative disorder: the Israel Penn International Transplant Tumor Registry experience. Transplantation Proceedings 37(2): 956-957, 2005

Biologic behavior of carcinoid tumors in solid organ transplant recipients: the Israel Penn international transplant tumor registry experience. Transplantation Proceedings 33(7-8): 3656-3657, 2001

Risk factors that influence survival in kidney transplant recipients with post-transplant lymphoproliferative disease A multivariate analysis. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 178A, 2002

Post-transplant lymphoproliferative disorder in adult renal transplant recipients: survival and prognosis. Leukemia and Lymphoma 57(2): 299-305, 2016

Incidence and risk factors for post-transplant lymphoproliferative disorder among renal transplant recipients. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 564A, 2002

Risk factors for post transplant lymphoproliferative disorder ptld in renal transplant recipients. Journal of the American Society of Nephrology 2(3): 795, 1991

MALToma: a Helicobacter pylori-associated malignancy in transplant patients: a report from the Israel Penn International Transplant Tumor Registry with a review of published literature. Transplantation 75(2): 225-228, 2003

Skin cancer following transplantation: the Israel Penn International Transplant Tumor Registry experience. Transplantation Proceedings 37(2): 962-963, 2005

Post-transplant lymphoproliferative disorder in lung transplant recipients The Cleveland Clinic experience. Laboratory Investigation 81(1): 226A, 2001

Post-Transplant Lymphoproliferative Disorder in Kidney Transplant Recipients: A Single-Center Experience in Japan. Therapeutic Apheresis and Dialysis 20(2): 165-173, 2016

Adenotonsillar hypertrophy and post-transplant lymphoproliferative disorder in pediatric renal transplant recipients. Pediatric Nephrology 19(4): 471-472, 2004

Post-transplant lymphoproliferative disorder in adult liver transplant recipients: a South American multicenter experience. Clinical Transplantation 27(4): E469-E477, 2014

Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. American Journal of Transplantation 5(12): 2894-2900, 2005